CellCeutix pharmaceutical company

Autism call transcript

On behalf of the officers of Cellceutix, I’d like to welcome you to our website and to this brief presentation on KM-391, our new compound for the treatment of Autism. My name is Leo Ehrlich and I'm the CFO of Cellceutix.

Before we discuss the data, I’d like to take this opportunity to express my personal thanks to the other Directors, Officers and employees of Cellceutix for the significant accomplishments we have made to date. More information about cellceutix is available on our website and in the public filings available at www.sec.gov.

I'm here to talk to our shareholders a little bit about our recent announcement that we've shown Positive Results With our Autism Compound.

To create this study with a highly indicative animal model is no easy task. Dr. Menon our CSO fortunately, was able to tap into some cutting edge research to find a promising model for our study. Without getting in to too much technical detail, the model involves injecting rats with a substance to simulate the conditions of autism.

Now let me say a little about the experiment we did. In a carefully conducted study, the animals were given our new compound, KM-391, orally over 90 days, at two dosage levels. At each dosage level, KM-391 was compared to both the “no treatment” group and the “active control” group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism.

Behavioral scoring was done by standard behavioral test scoring, plasticity was calculated by surgical scoring, and serotonin levels were obtained by immunohistochemistry.

The results showed that our Autism Compound KM-391 demonstrated significant improvements in the test animals on all the parameters we looked at. KM-391 was superior to both "no treatment" and "active control."

There are some noteworthy points which I’d like to advise you of

There are few if any proven treatments for autism, so research on new compounds is critical.

KM-391 is a unique compound. The patent process is underway.

We will be conducting further studies to try to move the compound toward human studies as rapidly as possible.

You can see a more detailed summary of the experiment by going to our press release and clicking on the pdf link.

We will be continuously updating you on this exciting development. As always, please send us your comments at This e-mail address is being protected from spam bots, you need JavaScript enabled to view it .

Thank you